OR-101 is an investigational next generation dual JAK3/ITK inhibitor that binds covalently and irreversibly to Cys909 in JAK3.

Ornovi's OR-101 is a highly selective next generation JAK3-ITK inhibitor with potentially a better safety profile than JAK inhibitors currently on the market, according to a presentation at the 25th World Congress of Dermatology Meeting 2023 in Singapore. 

Seemal Desai, MD, a dermatologist in Plano, Texas, will discuss the unique profile of OR-101, which positions it as a fast follow-on/next generation product to Ritlecitinib and other marketed JAK products, at the meeting.

"In my experience working with other JAK inhibitors, seeing the results of OR-101 in these animal models are quite remarkable," says April Armstrong, Associate, MD, Dean at Keck School of Medicine of University of Southern California in Los Angeles, in a news release. "This is a significant step forward for Ornovi, and I foresee that OR-101 has the potential to become a safe and effective alternative treatment for many patients, suffering from various inflammatory skin disorders."

OR-101 is an investigational next generation dual JAK3/ITK inhibitor that binds covalently and irreversibly to Cys909 in JAK3. The irreversible binding of OR-101 enables higher specificity and selectivity, leading to a potentially safer profile than the first generation JAKs, the Company states. 

"Ornovi is excited about this first presentation for OR-101, a novel JAK3 inhibitor at this prestigious conference.  This is our initial step to publicly share results from the non-clinical studies in well-established models, demonstrating the unique efficacy profile of OR-101," says Fauad Hasan, co-founder and CEO of Ornovi. "These results will enable Ornovi to advance its development program to the clinical stage later this year."